Your browser doesn't support javascript.
Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil.
Tess, Beatriz Helena; Granato, Celso Francisco Hernandez; Alves, Maria Cecília Goi Porto; Pintão, Maria Carolina Tostes; Nunes, Marcia Cavallari; Rizzatti, Edgar Gil; Reinach, Fernando de Castro.
  • Tess BH; Universidade de São Paulo, Faculdade de Medicina FMUSP, Departamento de Medicina Preventiva, São Paulo, SP, Brazil. Electronic address: beatriz.tess@usp.br.
  • Granato CFH; Grupo Fleury, Divisão de Pesquisa e Desenvolvimento, São Paulo, SP, Brazil.
  • Alves MCGP; Secretaria de Saúde do Estado de São Paulo, Instituto de Saúde, São Paulo, SP, Brazil.
  • Pintão MCT; Grupo Fleury, Divisão de Pesquisa e Desenvolvimento, São Paulo, SP, Brazil.
  • Nunes MC; Ipec Inteligência em Pesquisa e Consultoria, São Paulo, SP, Brazil.
  • Rizzatti EG; Grupo Fleury, Divisão de Pesquisa e Desenvolvimento, São Paulo, SP, Brazil.
  • Reinach FC; Universidade de São Paulo, Instituto de Química, Departamento de Bioquímica; São Paulo, SP, Brasil.
Braz J Infect Dis ; 25(4): 101604, 2021.
Article in English | MEDLINE | ID: covidwho-1397193
ABSTRACT

BACKGROUND:

São Paulo city has been one of the regions most affected by the COVID-19 pandemic in Brazil. Frequent asymptomatic and oligosymptomatic infections and poor access to diagnostic tests make serosurveys crucial to monitor the magnitude of the epidemic and to inform public health policies, such as vaccination plans.

OBJECTIVES:

To estimate, early in the epidemic, the seroprevalence of antibodies to SARS-CoV-2 in adults living in the six most affected districts in São Paulo city, and to assess potential associated risk factors.

METHODS:

This was a cross-sectional population-based survey of 1,152 households randomly selected from 72 census tracts. During the period May 4-12, 2020, 463 participants completed a questionnaire on sociodemographic characteristics and history of symptoms in the past two weeks, and provided a blood sample. Prevalence of SARS-CoV-2 antibodies was the outcome of interest and was estimated based on results of two immunoassays, Maglumi SARS-CoV-2 chemiluminescence assay Immunoglobulin (Ig) M (IgM) and IgG, and Roche electrochemiluminescence assay total Ig. Serum samples reactive to either assay were considered positive.

RESULTS:

Weighted overall seroprevalence was 6% (95%CI 3.9-8.3%). No association was observed between seropositivity and sex, age group or education level. Participants who reported black and brown skin color showed a 2.7 fold higher prevalence than people with white skin (p = 0.007). Among the 30 seropositive individuals, 14 (46.6%) reported no COVID-19 compatible symptoms in the past two weeks.

CONCLUSION:

This study represents the first assessment of SARS-CoV-2 seroprevalence in the city of São Paulo and 6% is the baseline estimate of a series of population-based seroprevalence surveys. Serological screening using sound serological assays is the key tool to monitoring temporal and geographic changes in the spread of the virus through an important epicenter of the COVID-19 pandemic in Brazil. Ultimately, it may inform prevention and control efforts.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Humans Country/Region as subject: South America / Brazil Language: English Journal: Braz J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Humans Country/Region as subject: South America / Brazil Language: English Journal: Braz J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article